GHRP-6

Volume: 5 MG

Dosage: 5 MG/VIAL

Clinical dosing: 100 - 400 mcg/day

Description:

GHRP-6 peptide (Growth hormone-releasing peptide-6) is synthetic analogue of endogenous opioid peptide met-enkephalin, includes unnatural D-amino acids, and belongs to the growth hormone secretagogues group and its ghrelin receptor agonists subgroup. Growth hormone secretagogues (GHS) lack opioid activity but are powerful stimulants of growth hormone production. Simultaneously GHS are distinct from growth hormone releasing hormone (GHRH) in that they share no sequence relation and derive their function through activation of a completely different receptor – growth hormone secretagogue receptor (GHSR; or often called simple as ghrelin receptor). Natural endogenous ligand of Growth hormone secretagogue receptors is endogenous hormone Ghrelin. All ghrelin receptor agonists (incl. GHRP-6 peptide) act as synthetic ghrelin mimetics. GHRP-6 peptide is structurally very similar to its predecessor GHRP-2 peptide. GHRP-6 is highly effective in increasing blood levels of HGH and IGF-1. Due to its properties, it is a promising candidate for the treatment of growth hormone deficiency, cachexia (wasting), eating disorders and obesity. Early studies translated into a new research era that inserted synthetic GHRPs also as promising cardio and cytoprotective candidates. A broad safety profile and a successful preclinical pharmacology nurtured the enthusiasm for GHRP-6 as a myocardial reperfusion damages-attenuating candidate. The existence of efficacious although occasional and fragmented clinical interventions in life-threatening conditions, along with the GHRP-6 multifactorial mechanism of action in myocardial infarction, ignite the initiative for a coherent clinical development.

Compound Specifications:

Originale product made in UK.